Skip to main content
TBPH
NASDAQ Life Sciences

Theravance Biopharma Reports Strong Q1 Results, Achieves Non-GAAP Profitability, and Resolves YUPELRI Litigation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$17.39
Mkt Cap
$872.29M
52W Low
$8.33
52W High
$21.03
52W Position info
109% above low
Off High info
17% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

TBPH has more than doubled off its 52-week low of $8.33.

Summary

Theravance Biopharma reported improved Q1 2026 financial results, achieving non-GAAP net income from operations and significantly reducing its net loss, driven by successful execution of its restructuring plan and a 15% increase in YUPELRI collaboration revenue. The company also announced the resolution of all Hatch-Waxman litigation for YUPELRI, securing its market exclusivity until 2039.


Key Events · Earnings and Guidance · TBPH

  • Achieved Non-GAAP Profitability

    Reported Q1 2026 non-GAAP net income from operations of $0.6 million, a significant improvement from a $8.6 million loss in Q1 2025.

  • Reduced Net Loss

    Net loss decreased to $4.9 million in Q1 2026 from $13.6 million in the prior year period.

  • YUPELRI Litigation Resolved

    All Hatch-Waxman litigation related to YUPELRI has been settled, securing market exclusivity until April 23, 2039.

  • Restructuring Progress On Track

    Operating expenses (excluding restructuring costs) decreased approximately 20% year-over-year, with the company on track to achieve a 60% reduction and $60-$70 million in annualized cash flow by Q3 2026.


Analysis · TBPH · Life Sciences

This 8-K filing signals a strong operational turnaround for Theravance Biopharma following the recent failure of its lead drug candidate and subsequent restructuring. The company's ability to achieve non-GAAP net income from operations and significantly reduce its net loss, alongside a 15% increase in YUPELRI revenue, demonstrates effective cost management and commercial execution. The resolution of all YUPELRI Hatch-Waxman litigation is a critical positive development, removing a significant overhang and securing the long-term revenue stream for its key commercial asset until 2039. The reaffirmation of a 60% operating expense reduction and projected $60-$70 million in annualized cash flow from Q3 2026, coupled with a robust $395 million cash balance and no debt, provides a solid financial foundation as the strategic review process continues.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TBPH was trading at $17.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $872.3M. The 52-week trading range was $8.33 to $21.03. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TBPH - Latest Insights

TBPH
Sep 18, 2026, 5:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.02
Real-time Price: $17.04 info
Change: +$0.024 (+0.14%) info
Market Cap: $884.176M info
TBPH
Sep 10, 2026, 11:03 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $17.04
Real-time Price: $17.04 info
Change: +$0.0090 (+0.05%) info
Market Cap: $884.176M info
TBPH
Sep 10, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.06
Real-time Price: $17.04 info
Change: -$0.016 (-0.09%) info
Market Cap: $884.176M info
TBPH
Aug 25, 2026, 4:54 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $17.03
Real-time Price: $17.04 info
Change: +$0.014 (+0.08%) info
Market Cap: $884.176M info
TBPH
Aug 25, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.03
Real-time Price: $17.04 info
Change: +$0.014 (+0.08%) info
Market Cap: $884.176M info